A Clinical Trial of Mass Balance of [14C] TQ05105 in Healthy Chinese Subjects
Status:
COMPLETED
Trial end date:
2024-08-20
Target enrollment:
Participant gender:
Summary
To analyze radioactivity excretion and pharmacokinetics in healthy subjects after a single oral dose of \[C\]TQ05105, identifying excretion routes, major metabolites, and biotransformation pathways. Secondary: To determine pharmacokinetics of TQ05105 and metabolites (e.g., TQ12550) via Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) and assess treatment safety.